BACKGROUND: Small proportions of all the elderly stroke patients receive recombinant tissue plasminogen activator (r-tPA) therapy, although old age is not a proven contraindication to intravenous thrombolytic therapy for acute ischemic stroke. The purpose of this study was to identify reasons for exclusion from r-tPA therapy and factors associated with the decision of r-tPA use in elderly patients with acute ischemic stroke. METHODS: From the acute stroke registries of 22 domestic university hospitals taking the r-tPA therapy from January 2007 to May 2010, we extracted data of all acute ischemic stroke patients who were aged 80 or over and arrived within onset 3 hours. For all patients, we assessed the eligibility of r-tPA therapy using National Institute of Neurological Disorders and Stroke (NINDS) r-tPA trial criteria. For eligible patients, we compared all clinical variables between patients who were treated with r-tPA and those who were not, and analyzed potential factors related to the decision of r-tPA use. RESULTS: A total of 494 patients were included in this study. 255 patients (51.6%) were excluded by NINDS r-tPA trial criteria and the major reasons for exclusion were minor neurological deficit (53.7%) and clinical improvement (17.3%). Among 239 patients who were eligible for r-tPA, 162 (32.8%) patients received r-tPA and 77 (15.6%) did not. Multivariable analysis showed that younger age, shorter time-delay from onset to admission, non-smoker, no history of prior stroke, good pre-stroke functional status and severe initial neurological deficit were independently associated with the decision of r-tPA use in the elderly stroke patients predictors for r-tPA treatment. CONCLUSION: In very elderly patients, mild neurological deficit on arrival and rapid clinical improvement in neurological symptoms were the main reasons for exclusion from thrombolytic therapy.
Aged ; Hospitals, University ; Humans ; National Institute of Neurological Disorders and Stroke ; Registries ; Stroke ; Thrombolytic Therapy ; Tissue Plasminogen Activator

BACKGROUND: Tissue plasminogen activator (tPA) is known to be effective if given within 3 hours after the onset of ischemic stroke. However, no study has been performed regarding what proportion of patients with acute ischemic stroke are actually given tPA within this time window. We therefore tried to figure out the performance rate of thrombolytic therapy and acute prognosis in hyperacute ischemic stroke patients. METHODS: We prospectively registered all the acute ischemic stroke patients. Thrombolyic therapy was decided strictly according to the NINDS tPA protocol and clinical monitoring was done by the NIH Stroke Scale (NIHSS). If tPA was not given, the reason was recorded. RESULTS: Among 613 acute stroke patients during a period of 2.5 years, there were 146 (23.8%) hyperacute ischemic stroke patients within 3 hours after onset. Even in the 29 cases of in-hospital stroke, the rate of early detection and management was only 27.6% (8 cases). Among the hyperacute stroke population, 56 (38.4%) patients were treated with the thrombolytic agent and 27 patients showed positive responses. Thrombolytic therapy was not tried in the remaining 90 patients. The most common reason was expectation of favorable outcome without thrombolysis. But among these patients, subsequent neurological worsening was noticed in 9 patients, particularly in those with vertebrobasilar stroke. CONCLUSIONS: Urgent notice and management of ischemic stroke needs to be more emphasized not only to the general public, but also to medical personnel. More close observation is especially needed in vertebrobasilar stroke cases (J Korean Neurol Assoc 19(5):447~451, 2001)
Humans ; National Institute of Neurological Disorders and Stroke ; Prognosis* ; Prospective Studies ; Stroke* ; Thrombolytic Therapy* ; Tissue Plasminogen Activator

BACKGROUND: The results of the National Institute of Neurological Disorders and Stroke (NINDS) r-tPA Stroke Trial generated considerable hope, but also concerns about whether their results could be replicated in clinical practice. We investigated whether r-tPA infusion could be administered in a community-based hospital, safely and effectively. METHODS: We analyzed, retrospectively, the data of 33 patients having suffered acute ischemic strokes and treated with intravenous r-tPA from February 2003 to December 2006. Safety was evaluated by intracranial hemorrhage, symptomatic intracranial hemorrhage, and mortality. Clinical neurological status was measured by National Institutes of Health Stroke Scale (NIHSS) at baseline, 24 hours, and 7 days after r-tPA treatment. Efficacy was assessed by the response rate of r-tPA using an improvement in the NIHSS by 4 or more points at 24 hours after treatment and the long-term out-come measured with the modified Rankin Scale (mRS) at 3 months after stroke. RESULTS: The median NIHSS was 18. Mean onset to needle time was 140+/-30 minutes. Of the 33 patients, 10 had intracranial hemorrhage and 2 had symptomatic intracranial hemorrhage. No deaths occurred. Fifteen patients showed improvement in their NIHSS by 4 or more points at 24 hours after r-tPA. On the mRS, 12 patients had a good outcome at 3 months. More specifically, 9 patients had no or minimal symptoms, 7 patients had mild to moderate disability, 10 patients had severe disability and 7 patients died. CONCLUSION: The safety andrd efficacy of administering intravenous r-tPA for acute ischemic stroke in a community-based hospital mirror the results of the NINDS stroke trial.
Humans ; Intracranial Hemorrhages ; National Institute of Neurological Disorders and Stroke ; National Institutes of Health (U.S.) ; Needles ; Retrospective Studies ; Stroke ; Tissue Plasminogen Activator

BACKGROUND: The results of the National Institute of Neurological Disorders and Stroke (NINDS) r-tPA Stroke Trial generated considerable hope, but also concerns about whether their results could be replicated in clinical practice. We investigated whether r-tPA infusion could be administered in a community-based hospital, safely and effectively. METHODS: We analyzed, retrospectively, the data of 33 patients having suffered acute ischemic strokes and treated with intravenous r-tPA from February 2003 to December 2006. Safety was evaluated by intracranial hemorrhage, symptomatic intracranial hemorrhage, and mortality. Clinical neurological status was measured by National Institutes of Health Stroke Scale (NIHSS) at baseline, 24 hours, and 7 days after r-tPA treatment. Efficacy was assessed by the response rate of r-tPA using an improvement in the NIHSS by 4 or more points at 24 hours after treatment and the long-term out-come measured with the modified Rankin Scale (mRS) at 3 months after stroke. RESULTS: The median NIHSS was 18. Mean onset to needle time was 140+/-30 minutes. Of the 33 patients, 10 had intracranial hemorrhage and 2 had symptomatic intracranial hemorrhage. No deaths occurred. Fifteen patients showed improvement in their NIHSS by 4 or more points at 24 hours after r-tPA. On the mRS, 12 patients had a good outcome at 3 months. More specifically, 9 patients had no or minimal symptoms, 7 patients had mild to moderate disability, 10 patients had severe disability and 7 patients died. CONCLUSION: The safety andrd efficacy of administering intravenous r-tPA for acute ischemic stroke in a community-based hospital mirror the results of the NINDS stroke trial.
Humans ; Intracranial Hemorrhages ; National Institute of Neurological Disorders and Stroke ; National Institutes of Health (U.S.) ; Needles ; Retrospective Studies ; Stroke ; Tissue Plasminogen Activator

Transient ischemic attack (TIA) often precede cerebral infarcts as a warning symptom. But the studies revealing the frequency and the correlation between preceding TIAs and following infarcts are rare. According to the western data, about one-quarter of the patients with cerebral infarct have been supposed to have the previous history of TIAs. We prospectively studied the exact frequency, clinical presentation, and presumed causes of TIAs preceding cerebral infarct. Ninety five patients diagnosed as acute cerebral infarction were interviewed whether they had had previous episodes of TIA. 4 check-list using ordinary language was used, and NINDS diagnostic criteria was applied on the consensus between several neurologists. Seventeen patients (18%) had history of preceding TIAs. Carotid territory was affected in 11 patients (65%), while vertebrobasilar in 4(24%) and undetermined in 2. Duration was less than an hour in 10 patients(59%), and attacks were multiple in about half. Time interval between the last attack and infarction was less than one week in 10 cases(59%). Incidence of recent TIA ((1 month) was 22% in large artery disease(LAD), 11% In cardioembolism(CE), 9% in small-artery disease(SAD), and 7% in mixed etiology. Conclusion, TIAs preceding cerebral infarcts are not rare, but seems to be less common in Koreans than in Caucasians. As expected, atherothrombosis of large artery is supposed to be the leading cause of TIAs.
Arteries ; Cerebral Infarction ; Consensus ; Humans ; Incidence ; Infarction ; Ischemic Attack, Transient* ; National Institute of Neurological Disorders and Stroke ; Prospective Studies

BACKGROUND: Neuropsychological Differentiation between Alzheimer's disease and vascular dementia has been controversial. The aim of this study was to detect neuropsychological differences between Alzheimer's disease (AD) and vascular dementia (VD). METHODS: Twenty one patients who met the criteria for probable AD according to the National Institute of Neurological Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and 22 patients who met criteria for probable VD according to the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN), were included in this study. These two dementia groups were matched for age, sex, education, Mini-Mental State Examination score, and severities of dementia. All patients underwent the Seoul Neuropsychological Screening Battery (SNSB). RESULTS: Patients with VD showed greater deficits in verbal fluency (P<.05) than AD patients. However, AD patients, compared with VD patients, showed greater deficits in verbal memory functions including the 3 words recall task. Otherwise, no significant between-group differences were found in task results. CONCLUSIONS: Neuropsychologically, patients with VD differ from patients with AD only in a few cognitive domains. (J Korean Neurol Assoc 19(2):143~148, 2001)
Alzheimer Disease* ; Dementia ; Dementia, Vascular* ; Education ; Humans ; Mass Screening ; Memory ; National Institute of Neurological Disorders and Stroke ; Neuropsychological Tests ; Neurosciences ; Seoul

BACKGROUND: Neuropsychological Differentiation between Alzheimer's disease and vascular dementia has been controversial. The aim of this study was to detect neuropsychological differences between Alzheimer's disease (AD) and vascular dementia (VD). METHODS: Twenty one patients who met the criteria for probable AD according to the National Institute of Neurological Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and 22 patients who met criteria for probable VD according to the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN), were included in this study. These two dementia groups were matched for age, sex, education, Mini-Mental State Examination score, and severities of dementia. All patients underwent the Seoul Neuropsychological Screening Battery (SNSB). RESULTS: Patients with VD showed greater deficits in verbal fluency (P<.05) than AD patients. However, AD patients, compared with VD patients, showed greater deficits in verbal memory functions including the 3 words recall task. Otherwise, no significant between-group differences were found in task results. CONCLUSIONS: Neuropsychologically, patients with VD differ from patients with AD only in a few cognitive domains. (J Korean Neurol Assoc 19(2):143~148, 2001)
Alzheimer Disease* ; Dementia ; Dementia, Vascular* ; Education ; Humans ; Mass Screening ; Memory ; National Institute of Neurological Disorders and Stroke ; Neuropsychological Tests ; Neurosciences ; Seoul

BACKGROUND: Intravenous recombinant tissue plasminogen activator (r-tPA) infusion is the only established treatment for acute ischemic stroke so far. We explored whether the demonstrated efficacy of r-tPA could be applied to communi-ty-based hospitals in Korea and whether the immediate improvements after r-tPA infusion had any predicting value for long-term outcomes. METHODS:Twenty-six patients (mean age, 69; 46% female) with acute ischemic stroke were treated with r-tPA, abiding by the National Institute of Neurological Disorders and Stroke (NINDS) protocol. The Neurological status was measured with the National Institutes of Health Stroke Scale (NIHSS) at baseline, at 1 hour after r-tPA , at 24 hours, and at 7 days and the functional outcome was evaluated with the modified Rankin scale (mRS) and Barthel Index at 90 days after stroke. RESULTS: Of 26 patients, 16 (62%) made full recovery or became independent, 4 (15%) had severe physical disability, and 6 (23%) patients died. Three patients (11.5%) had intracranial hemorrhage (asymptomatic, 2; symptomatic, 1). There were no significant differences in age, sex, risk factors, baseline NIHSS scores, hemorrhagic complication, initial brain CT abnormalities, and onset to needle time between good (full recovery or mRS 0-2) and poor groups (mRS 3-5 or death) at day 90, except for the improvement of NIHSS examined at 1 hour after r-tPA (repeated measured ANOVA test, p<0.01). CONCLUSIONS The NINDS r-tPA protocol is feasible in the community-based hospitals in Korea with the safety and efficacy comparable to the results of NINDS r-tPA trials. In addition, we suggest that the immediate neurological improvement after r-tPA be a predictor for favorable long-term outcomes. (J Korean Neurol Assoc 19(4):364~369, 2001)
Brain ; Cerebral Infarction ; Humans ; Intracranial Hemorrhages ; Korea ; National Institute of Neurological Disorders and Stroke ; National Institutes of Health (U.S.) ; Needles ; Risk Factors ; Stroke* ; Thrombolytic Therapy ; Tissue Plasminogen Activator ; Treatment Outcome

BACKGROUND: To evaluate usefulness of cerebrospinal aspartate aminotransferase(AST) as a biologic marker for differentiation of Alzheimer's disease(AD) and Vascular dementia(VD) METHODS: A consecutive series of patients who met either the criteria of the National Institute of Neurological Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association(NINCDSADRDA) for probable AD or National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences(NINDS-AIREN) criteria for porbable VD were included in the study. Enzymatic determinations in cere brospinal fluid of aspartate aminotransferase in cerebrospinal fluid of aspartate aminotransferase and serologic analysis of apolipoprotein E were performed in 17 patients with AD and in 15 patients with VD. And we compared CSF AST of AD with that of VD. RESULTS: We found no difference of CSF AST concentration between patients with Alzheimer's disease and vascular dementia. Cerebrospinal AST activity also did not correlate with K-MMSE score, serum AST activity, Functional inde-pence measure(FIM) as a ADL(Activity of daily living), and presence of Apolipoprotein E4 allele in AD. Only serum AST of VD shows correlation with CSF AST. CONCLUSION: These findings suggest that cerebrospinal AST concentration is not useful maker for differentiation between AD and VD.
Alleles ; Alzheimer Disease* ; Apolipoprotein E4 ; Apolipoproteins ; Aspartate Aminotransferases* ; Aspartic Acid* ; Biomarkers ; Cerebrospinal Fluid* ; Dementia, Vascular* ; Humans ; National Institute of Neurological Disorders and Stroke

PURPOSE: In many other countries, based on research, recombinant tissue plasminogen activator (r-tPA) has been approved for the treatment of acute ischemic strokes. However, in Korea, little research has been done till now, in spite of using r-tPA widely. We sought to assess the feasibility and the efficacy of treatment and to evaluate the prognosis and complications at the violation of using r-tPA. Our study was compared with other previous studies. METHODS: A retrospective review is presented of 25 the cases of patients with acute ischemic stroke treated with rtPA according to the National Institutes of Neurological Disorders and Strokes (NINDS) protocol. We classified the groups by protocol violation (time, blood pressure, and computed tomography). We then analyzed neurologic outcomes by using the National Institutes of Health Strokes Scale (NIHSS) and complications based on whether or not intracerebral hemorrhage (ICH) had occurred. RESULTS: Of the 25 patients (mean age: 57 males: 19), 6 had time violation (onset time > 180 min), 4 had blood-pressure violation (systolic BP > 185 mmHg), 5 had CT violation (low density at initial CT). The NIHSS score improved in 64% of all patients after 24 hours. However, improvement was lower in the case of deviation present than it was in the case of deviation absent (time, blood pressure, and CT, respectively, 20%, 50%, and 40%; p-value respectively 0.0274, 0.8350, and 0.4125). ICH occurred in 6 cases, but in cases of deviation present, ICH occurred at a greater frequency. CONCLUSION: Our safety and feasibility of outcome compared favorably with NINDS and other previous studies. In addition, we confirmed that the presence of protocol deviation was associated a poor outcome.
Academies and Institutes ; Blood Pressure ; Cerebral Hemorrhage ; Humans ; Korea ; Male ; National Institute of Neurological Disorders and Stroke ; National Institutes of Health (U.S.) ; Nervous System Diseases ; Prognosis* ; Retrospective Studies ; Stroke* ; Thrombolytic Therapy ; Tissue Plasminogen Activator